DexCom, Inc.

Report azionario NasdaqGS:DXCM

Capitalizzazione di mercato: US$23.2b

DexCom Crescita futura

Criteri Future verificati 2/6

DexCom prevede che gli utili e i ricavi cresceranno rispettivamente di 15.4% e 10.6% all'anno. Si prevede che l'EPS crescerà di 14.2% all'anno. Si prevede che il ritorno sul capitale proprio sarà di 30.5% in 3 anni.

Informazioni chiave

15.4%

Tasso di crescita degli utili

14.20%

Tasso di crescita dell'EPS

Medical Equipment crescita degli utili15.9%
Tasso di crescita dei ricavi10.6%
Rendimento futuro del capitale proprio30.50%
Copertura analitica

Good

Ultimo aggiornamento04 May 2026

Aggiornamenti recenti sulla crescita futura

Earnings Beat: DexCom, Inc. Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models

Nov 02
Earnings Beat: DexCom, Inc. Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models

Recent updates

Type 2 Coverage Expansion And AI Features Will Shape A Balanced Long Term Outlook

Catalysts About DexCom DexCom develops and sells continuous glucose monitoring systems used by people with diabetes around the world. What are the underlying business or industry changes driving this perspective?

DXCM: AI Coaching And Share Repurchases Will Support Future Healthcare Momentum

Analysts have made a small trim to DexCom's implied value, cutting the analyst price target by about $0.25, as they balance slightly softer modeled growth and margins with generally supportive recent research, including multiple target increases following the latest medtech sector updates. Analyst Commentary Recent research on DexCom reflects a mix of optimism and caution as analysts adjust their models and targets across the medtech group.

DXCM: AI Coaching And Buybacks Will Support Future Healthcare Momentum

Analysts have nudged DexCom's fair value estimate higher to $87.13 from $86.12, citing a series of upward price target revisions that cluster around the low to mid $80s, while one firm maintains a more cautious view focused on rising competition. Analyst Commentary Recent research on DexCom reflects a split view, with several bullish analysts lifting price targets into the low to mid US$80s, while at least one bearish voice is positioning closer to the low US$70s.

DXCM: AI Coaching And Buybacks Will Support Future Market Share Confidence

DexCom's fair value estimate edges up by about $0.27 as analysts fine tune assumptions on the discount rate, revenue growth, profit margin, and future P/E, following a mix of price target changes across the Street, including recent upward revisions toward $84 to $86 and a lower $71 target tied to competition concerns. Analyst Commentary Recent Street research on DexCom reflects a split view, with some firms nudging targets higher into the mid $80s and others pushing back toward the low $70s on competition concerns.

DXCM: AI Coaching And Share Repurchases Will Support Long-Term Confidence

DexCom's intrinsic value estimate nudged higher to $85.85, with analysts modestly lifting price targets, often in the $1 to $12 range, as they weigh recent target increases against a Barclays downgrade that highlights rising competitive pressure in continuous glucose monitoring. Analyst Commentary Recent research on DexCom reflects a split tape, with several firms adjusting price targets higher by amounts in the low single digits to low teens, while one major firm has moved to a more cautious stance with a lower target and an Underweight rating.

DXCM: Medicare Support And AI Coaching Rollout Will Sustain Long-Term Confidence

Our updated DexCom narrative reflects a small increase in fair value to $85.46. Analysts point to a mix of modestly lower assumed revenue growth, slightly higher profit margin expectations, a reduced future P/E multiple, and a series of recent price target adjustments that are mostly higher in dollar terms despite some concerns around rising competition.

The Strong Earnings Posted By DexCom (NASDAQ:DXCM) Are A Good Indication Of The Strength Of The Business

Feb 19
The Strong Earnings Posted By DexCom (NASDAQ:DXCM) Are A Good Indication Of The Strength Of The Business

DXCM: Medicare Support And AI Coaching Features Will Sustain Long-Term Confidence

Analysts made only a slight upward tweak to the DexCom price target to about US$85, reflecting small adjustments to their growth, margin and P/E assumptions as they balance caution on rising competition with support from recent positive research updates. Analyst Commentary Recent research on DexCom reflects a split view, with some analysts highlighting supportive policy signals and valuation upside, while others focus on intensifying competition and reduced price targets.

DXCM: Medicare Support And 2026 Sensor Expansion Will Sustain Long-Term Confidence

Our DexCom price target edges down to about $85 from $85.27, reflecting slightly lower assumed profit margins and P/E multiple, partly offset by analysts citing supportive Medicare reimbursement commentary and mixed Street views on competition, valuation, and 2026 guidance. Analyst Commentary Recent research on DexCom highlights a clear split between bullish and bearish analysts, with views clustering around competition, execution on guidance, and how much investors are willing to pay for the stock through the P/E multiple.

DXCM: Medicare Support And New Sensor Duration Will Sustain Long-Term Confidence

Analysts nudged their fair value estimate for DexCom slightly higher to about $85 per share, citing a generally supportive regulatory backdrop for continuous glucose monitors and noting that recent price target cuts still reflect confidence in the company’s long term patient growth and product profile. Analyst Commentary Recent research updates on DexCom highlight a mix of optimism around the core continuous glucose monitor franchise and caution around guidance, pricing, and execution into 2026.

DXCM: Medicare Reimbursement Stability Will Support Confidence Despite Emerging Legal And Safety Headlines

Analysts have nudged our DexCom fair value estimate slightly higher, from $84.31 to $84.85, as they balance recent price target cuts with continued Buy and Outperform ratings that point to resilient growth, stable margins, and a favorable regulatory and product backdrop. Analyst Commentary Street research continues to reflect a constructive long term view on DexCom, even as recent reports incorporate more conservative assumptions and lower base case price targets.

DXCM: Medicare Payment Developments Will Drive Confidence Despite Recent Short-Term Weakness

DexCom's analyst price target has decreased modestly to approximately $84.31 from $84.96, as analysts cite a mix of positive Medicare policy developments and tempered optimism following company guidance updates and recent survey data. Analyst Commentary Recent analyst research on DexCom reflects both optimism about the company's long-term prospects and concerns regarding near-term execution and growth trends.

DXCM: Share Recovery Likely With Positive Setup Expected For 2026

Analysts have lowered their price targets for DexCom, reducing the fair value estimate from $98.40 to $84.96. This reflects a reaction to recent conservative guidance, weaker growth outlook, and updated margin expectations.

Earnings Beat: DexCom, Inc. Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models

Nov 02
Earnings Beat: DexCom, Inc. Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models

DXCM: Expanding Reimbursement Will Drive Gains Despite Market Uncertainty

The consensus analyst price target for DexCom was recently lowered, with the average fair value estimate moving down by less than $1 to approximately $98.40. Analysts cite investor concerns around the company’s conservative guidance and gross margin pressure, but remain generally positive on long-term growth and patient retention trends.

Insurance Reimbursement And Digital Health Integration Will Unlock Global Potential

DexCom's average analyst price target has decreased by approximately $1.58 to around $98.96. Analysts are recalibrating their outlook in light of mixed survey results and a shift in assumptions around reimbursement trends and profitability expectations.

DexCom May Be The Most Underrated Growth Story In Healthcare

Oct 06

Insurance Reimbursement And Digital Health Integration Will Unlock Global Potential

Analysts have modestly reduced DexCom's fair value estimate by approximately $1.54 to $100.54 per share. This change reflects slightly lower revenue growth projections and recent adjustments in price targets based on mixed survey data and evolving reimbursement trends.

We Think DexCom (NASDAQ:DXCM) Can Manage Its Debt With Ease

Jul 22
We Think DexCom (NASDAQ:DXCM) Can Manage Its Debt With Ease

DexCom's (NASDAQ:DXCM) Returns On Capital Are Heading Higher

Jul 09
DexCom's (NASDAQ:DXCM) Returns On Capital Are Heading Higher

Is DexCom, Inc. (NASDAQ:DXCM) Trading At A 24% Discount?

May 16
Is DexCom, Inc. (NASDAQ:DXCM) Trading At A 24% Discount?

DexCom: Valuation Does Not Factor In Slowing Growth

Mar 04

DexCom: Fairly Priced In 2025; Why I'm Not Expecting A Share Price Comeback

Jan 17

DexCom: Brighter 2025 From Stelo Ramp

Dec 10

DexCom Growing Into Its Valuation, But Still No Bargain

Oct 25

DexCom Q3 Preview: Walking On Eggshells With Its Channel Relationships

Oct 16

DexCom: Investors Discounting Long CGM Growth Runway

Sep 19

DexCom Q2 Earnings: Traditional Market Overreaction

Aug 07

Previsioni di crescita degli utili e dei ricavi

NasdaqGS:DXCM - Stime future degli analisti e dati finanziari passati (USD Millions )
DataRicaviUtiliFlusso di cassa liberoLiquidità dell'operazioneAvg. Numero di analisti
12/31/20286,5351,4161,5992,05918
12/31/20275,8491,1601,2591,73725
12/31/20265,2279619931,44825
3/31/20264,8189301,4291,783N/A
12/31/20254,6628361,0771,441N/A
9/30/20254,5167211,0621,448N/A
6/30/20254,301572571988N/A
3/31/20254,148535575964N/A
12/31/20244,033576631990N/A
9/30/20243,954681535822N/A
6/30/20243,935667666891N/A
3/31/20243,802639584802N/A
12/31/20233,622542512749N/A
9/30/20233,403377500747N/A
6/30/20233,198358466771N/A
3/31/20233,023293416754N/A
12/31/20222,910341305670N/A
9/30/20222,793244261643N/A
6/30/20222,673230216597N/A
3/31/20222,57225895486N/A
12/31/20212,44921753443N/A
9/30/20212,319577140509N/A
6/30/20212,170562101409N/A
3/31/20212,027530236502N/A
12/31/20201,927550277476N/A
9/30/20201,821231264447N/A
6/30/20201,716205209394N/A
3/31/20201,601148131305N/A
12/31/20191,476101N/A315N/A
9/30/20191,351-171N/A205N/A
6/30/20191,222-170N/A167N/A
3/31/20191,128-130N/A144N/A
12/31/20181,032-127N/A123N/A
9/30/201891543N/A131N/A
6/30/2018833-5N/A110N/A
3/31/2018761-33N/A83N/A
12/31/2017719-50N/A92N/A
9/30/2017669-48N/A64N/A
6/30/2017633-65N/A51N/A
3/31/2017599-88N/A57N/A
12/31/2016573-66N/A56N/A
9/30/2016533-57N/A54N/A
6/30/2016490-80N/A49N/A
3/31/2016445-64N/A45N/A
12/31/2015402-58N/A49N/A
9/30/2015356-58N/A46N/A
6/30/2015319-20N/A40N/A

Previsioni di crescita futura degli analisti

Guadagni vs tasso di risparmio: La crescita prevista degli utili di DXCM ( 15.4% all'anno) è superiore al tasso di risparmio ( 3.5% ).

Guadagni vs Mercato: Si prevede che gli utili di DXCM ( 15.4% all'anno) cresceranno più lentamente rispetto al mercato US ( 16.1% all'anno).

Guadagni ad alta crescita: Si prevede che gli utili di DXCM cresceranno, ma non in modo significativo.

Ricavi vs Mercato: Si prevede che il fatturato di DXCM ( 10.6% all'anno) crescerà più lentamente rispetto al mercato US ( 11.3% all'anno).

Ricavi ad alta crescita: Si prevede che il fatturato di DXCM ( 10.6% all'anno) crescerà più lentamente di 20% all'anno.

Previsioni di crescita dell'utile per azione

Rendimento futuro del capitale proprio

ROE futuro: Si prevede che il Return on Equity di DXCM sarà elevato tra 3 anni ( 30.5 %)

Scoprire le aziende in crescita

7D

1Y

7D

1Y

7D

1Y

Analisi aziendale e situazione dei dati finanziari

DatiUltimo aggiornamento (ora UTC)
Analisi dell'azienda2026/05/05 09:43
Prezzo dell'azione a fine giornata2026/05/05 00:00
Utili2026/03/31
Utili annuali2025/12/31

Fonti dei dati

I dati utilizzati nella nostra analisi aziendale provengono da S&P Global Market Intelligence LLC. I seguenti dati sono utilizzati nel nostro modello di analisi per generare questo report. I dati sono normalizzati, il che può comportare un ritardo nella disponibilità della fonte.

PacchettoDatiTempisticaEsempio Fonte USA *
Dati finanziari della società10 anni
  • Conto economico
  • Rendiconto finanziario
  • Bilancio
Stime di consenso degli analisti+3 anni
  • Previsioni finanziarie
  • Obiettivi di prezzo degli analisti
Prezzi di mercato30 anni
  • Prezzi delle azioni
  • Dividendi, scissioni e azioni
Proprietà10 anni
  • Top azionisti
  • Insider trading
Gestione10 anni
  • Team di leadership
  • Consiglio di amministrazione
Sviluppi principali10 anni
  • Annunci aziendali

* Esempio per i titoli statunitensi, per i titoli non statunitensi si utilizzano forme e fonti normative equivalenti.

Se non specificato, tutti i dati finanziari si basano su un periodo annuale ma vengono aggiornati trimestralmente. Si tratta dei cosiddetti dati TTM (Trailing Twelve Month) o LTM (Last Twelve Month). Per saperne di più.

Modello di analisi e Snowflake

I dettagli del modello di analisi utilizzato per generare questo report sono disponibili sulla nostra pagina Github; abbiamo anche guide su come utilizzare i nostri report e tutorial su Youtube.

Scoprite il team di livello mondiale che ha progettato e realizzato il modello di analisi Simply Wall St.

Metriche di settore e industriali

Le nostre metriche di settore e di sezione sono calcolate ogni 6 ore da Simply Wall St; i dettagli del nostro processo sono disponibili su Github.

Fonti analitiche

DexCom, Inc. è coperta da 52 analisti. 25 di questi analisti ha fornito le stime di fatturato o di utile utilizzate come input per il nostro report. Le stime degli analisti vengono aggiornate nel corso della giornata.

AnalistaIstituzione
Jeffrey JohnsonBaird
Matthew MiksicBarclays
Travis SteedBarclays